XORTX starts GMP manufacturing for XORLO to support XRX-OXY-102 gout trial

• XORTX launched GMP manufacturing of XORLO, its oxypurinol formulation, to supply the planned two-part XRX-OXY-102 gout study.
• The program advances based on prior supportive clinical results already presented, alongside FDA discussions.
• Production covers drug substance and commercial-scale tablets intended to match potential US marketing-approval material.
• Validation and stability work is expected to support a future FDA marketing application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609101605PRIMZONEFULLFEED9824912) on September 10, 2026, and is solely responsible for the information contained therein.